Pharming Group Management
Management criteria checks 3/4
Pharming Group's CEO is Fabrice Chouraqui, appointed in Mar 2025, has a tenure of 1.08 years. total yearly compensation is $1.84M, comprised of 37.3% salary and 62.7% bonuses, including company stock and options. directly owns 0.94% of the company’s shares, worth €9.88M. The average tenure of the management team and the board of directors is 2.6 years and 4.9 years respectively.
Key information
Fabrice Chouraqui
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 37.31% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.9% |
| Management average tenure | 2.6yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | US$2m | US$688k | US$3m |
Compensation vs Market: Fabrice's total compensation ($USD1.84M) is about average for companies of similar size in the German market ($USD1.96M).
Compensation vs Earnings: Insufficient data to compare Fabrice's compensation with company performance.
CEO
Fabrice Chouraqui
Mr. Fabrice Chouraqui, Ph D., PharmD, serves as the Chief Executive Officer and Executive Director of Pharming Group N.V. since March 4, 2025. He served as the Chief Executive Officer at Cellarity, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 1.1yrs | US$1.84m | 0.94% € 9.9m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operations Officer | 6.7yrs | no data | 0.17% € 1.8m | |
| VP of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Legal & Compliance Officer | 4.9yrs | no data | 0.11% € 1.2m | |
| Chief People Officer | 1.3yrs | no data | 0.018% € 188.0k | |
| Chief Medical Officer | 4.8yrs | no data | 0.14% € 1.5m | |
| Chief Business Officer | 2.6yrs | no data | 0.059% € 621.6k | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Medical Director | no data | no data | no data | |
| Consultant | 4.8yrs | no data | no data |
Experienced Management: PHGN's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 1.1yrs | US$1.84m | 0.94% € 9.9m | |
| Independent Non-Executive Director | 4.9yrs | US$109.00k | 0.022% € 227.3k | |
| Independent Non-Executive Vice Chairman | 5.3yrs | US$100.00k | 0.025% € 264.3k | |
| Independent Non-Executive Director | 5.3yrs | US$114.00k | 0.025% € 264.3k | |
| Non-Executive Chairman of Board | 2.6yrs | US$167.00k | 0.015% € 156.0k | |
| Non Executive Director | less than a year | US$73.00k | 0.0030% € 31.5k | |
| Independent Non-Executive Director | 4.9yrs | US$114.00k | 0.022% € 227.3k |
Experienced Board: PHGN's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 11:09 |
| End of Day Share Price | 2026/04/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharming Group N.V. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| John Savin | Edison Investment Research |
| Simon Scholes | First Berlin Equity Research GmbH |